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http://dx.doi.org/10.1016/j.ccr.2013.05.021SUMMARYSustained tumor progression has been attributed to a distinct population of tumor-propagating cells (TPCs).
To identify TPCs relevant to lung cancer pathogenesis, we investigated functional heterogeneity in tumor
cells isolated from Kras-driven mouse models of non-small-cell lung cancer (NSCLC). CD24+ITGB4+Notchhi
cells are capable of propagating tumor growth in both a clonogenic and an orthotopic serial transplantation
assay.While all four Notch receptorsmark TPCs, Notch3 plays a nonredundant role in tumor cell propagation
in two mouse models and in human NSCLC. The TPC population is enriched after chemotherapy, and the
gene signature of mouse TPCs correlates with poor prognosis in human NSCLC. The role of Notch3 in tumor
propagation may provide a therapeutic target for NSCLC.INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide (Je-
mal et al., 2011), and non-small-cell lung cancer (NSCLC) ac-
counts for approximately 80% of cases. Despite aggressive
frontline treatment, the 5-year survival rate remains poor for
most patients. A functional hierarchy in regard to tumor-propa-
gating capacity is a well-established feature of some cancers
and may account for an incomplete therapeutic response. Cells
with an increased capacity to sustain tumor propagation are
called tumor-propagating cells (TPCs, also referred to as cancer
stem cells) and can be prospectively identified using cell surface
markers. TPCs have been identified in several solid tumors (Al-
Hajj et al., 2003; Hermann et al., 2007; O’Brien et al., 2007; SinghSignificance
A distinct population of tumor cells capable of tumor propaga
lecular mechanisms that drive self-renewal and propagation in
tified a set of surfacemarkers that greatly enriches cells with tum
tumor-propagating cell (TPC) subpopulation is enriched after c
predictive of poor prognosis in humanNSCLC. Furthermore, we
themediation of propagation and self-renewal of TPCs. Thus, N
Notch3 may be a useful therapeutic strategy for some cases oet al., 2004). Additionally, TPCs have been linked to chemoresist-
ance and radiation resistance as well as metastasis (Bao et al.,
2006; Chen et al., 2012; Hermann et al., 2007; Phillips et al.,
2006). In NSCLC, several reports have described isolation of
TPCs with surface markers including CD133, CD44, or CD166
(Eramo et al., 2008; Leung et al., 2010; Zhang et al., 2012). How-
ever, other studies have yielded conflicting results (Cui et al.,
2011; Meng et al., 2009; Tirino et al., 2009), and none of these
markers have been shown to be functionally required for the
TPC state. Furthermore, whether TPCs in NSCLC are linked to
chemoresistance and if their prevalence is associated with the
prognosis of human NSCLC have not been determined.
The use of mousemodels of cancer provides an opportunity to
assess the influence of specific genotypes commonly found intion has been identified in some cancers. However, the mo-
these cells remain incompletely understood. Here, we iden-
or-propagating ability in twomousemodels of NSCLC. This
hemotherapy, and the gene expression signature of TPCs is
demonstrate a specific and nonredundant role for Notch3 in
otch receptors play specific roles in NSCLC, and blockade of
f NSCLC.
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Tumor-Propagating Cells in NSCLCNSCLC on TPC frequency. CD45PecamSca1+ have been pro-
posed to be genotype-specific surface markers of TPCs (Curtis
et al., 2010; Kim et al., 2005) only in tumors with the KrasG12D;
Trp53fl/fl genotype but not in tumors of the KrasG12D or
EGFRT790M-L858R genotypes. However, a residual mesen-
chymal cell component has been reported using the
CD45PecamSca1+ enrichment strategy, questioning the
specificity of these markers (McQualter et al., 2009; Teisanu
et al., 2009). Contamination of tumor stroma is a particularly
important issue in the KrasG12D; Trp53fl/fl lung tumor model
because these tumors are characterized by a significant desmo-
plastic stromal component (Jackson et al., 2005).
The self-renewal pathways required for maintaining long-term
tumor propagation potential in NSCLC are not well defined. The
Notch pathway has been previously linked to regulation of self-
renewal in TPCs of colon, breast, and brain cancer (Fan et al.,
2010; Harrison et al., 2010; Hoey et al., 2009). Overexpression
of N1ICD in murine alveolar epithelium initiates hyperplasia and
eventually lung adenomas (Allen et al., 2011). In addition, Notch1
and Notch3 signaling promote tumor cell proliferation and inhibit
cell apoptosis in some NSCLC cell lines (Haruki et al., 2005; Ko-
nishi et al., 2010; Westhoff et al., 2009). In a mouse model of
NSCLC with mutant Kras but wild-type for Trp53, genetic or
pharmacologic blockade of signaling from all four Notch recep-
tors leads to decreased tumorigenesis (Maraver et al., 2012).
These studies support the hypothesis that Notch signaling plays
an important pro-oncogenic role in NSCLC. However, whether
Notch marks TPCs with relevance to chemotherapy resistance
and prognosis in primary tumor models has not been estab-
lished. In addition, the specific role of each Notch receptor in
lung tumorigenesis as well as the specific role of each Notch re-
ceptor in establishing heterogeneity within lung tumors have not
been defined.
We sought to develop an improved approach to positively
identify tumor cells and separate them from tumor stromal to
determine whether tumors arising in either the KrasG12D or
KrasG12D; Trp53fl/fl mouse models demonstrate evidence of
functional heterogeneity consistent with the presence of a rare
TPC population. Furthermore, we sought to determine whether
loss of Trp53 alters the frequency or characteristics of the TPC
population. Identification of a TPC population in mouse models
of lung cancer could be important because the functional char-
acteristics of TPCsmay be common between themouse and hu-
man disease. In particular, while some studies have suggested
that TPCs are chemoresistant, there is a paucity of data confirm-
ing this phenotype in vivo. In addition, the self-renewal pathways
that are critical for maintenance of TPCs in many cancers remain
to be described. Therefore, a key goal of our studies was to iden-
tify critical regulators of TPC self-renewal in lung cancer. The
comparative cross-species strategy employed here, combining
mouse models with the analysis of primary patient-derived sam-
ples, may be applicable to other TPC studies.
RESULTS
Isolation and Characterization of Fluorescent-Labeled
Tumor Cells from Mouse Models of NSCLC
Efforts to isolate TPCs are confounded by the presence of abun-
dant stroma within the tumor (Jackson et al., 2005). To allow for60 Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc.positive identification of tumor cells and separation from tumor
stroma, KrasG12D or KrasG12D; Trp53fl/fl mice were crossed with
conditional reporter lines carrying Cre-inducible alleles of either
eYFP or tdRFP (Luche et al., 2007; Srinivas et al., 2001; Fig-
ure S1A available online). Analysis of the lung epithelium of these
mice 1 week after infection with an adenovirus expressing Cre
(AdCre) revealed rare, fluorescent cells distributed throughout
the distal lung epithelium. These fluorescent cells showed evi-
dence of proliferation only in mice carrying a mutation of either
KrasG12D or KrasG12D; Trp53fl/fl (Figure S1B). Therefore, AdCre
infection of compound mutant reporter mice led to the develop-
ment of lung tumors in which tumor cells were labeledwith a fluo-
rescent marker that could be positively identified and isolated by
flow cytometry (FACS; Figures S1C and S1D).
FACS analysis of lungs from these mice identified two pop-
ulations of fluorescent cells, distinguished by the expression of
lineage markers (CD45, PECAM, and Ter119; Lin+; Figure 1A).
A majority of Lin+ YFP+ cells were positive for F4/80 (Figure S1E),
suggesting that they were tumor-associated macrophages. In
contrast, Lin YFP+ cells were Epcam+, supporting an epithelial
origin (Figure S1F). Lin YFP+ cells also demonstrated higher
expression of the lung epithelial markers Nkx2.1 (thyroid tran-
scription factor 1, TTF-1) and Sftpc (surfactant protein C, SP-
C), relative to Lin+YFP+ cells (Figure 1A). Finally, the tumor origin
of LinYFP+ cells was supported by the absence of an unrecom-
bined ‘‘two-lox,’’ KrasG12D-specific band (LSL allele) together
with the presence of a ‘‘one-lox’’ recombined allele (Figure 1B).
Thus, the combination of genetic labeling and cell sorting al-
lowed for the isolation of a highly enriched population of tumor
cells depleted of normal lung parenchyma, tumor stroma, and
immune infiltration. We use ‘‘tumor cells’’ to refer to this highly
purified Linfluorescence+ population hereafter.
To establish the tumorigenic potential of tumor cells from the
KrasG12D or KrasG12D; Trp53fl/fl models, Lin fluorescence+ cells
were transplanted into recipient immunocompromised mice via
intratracheal intubation. Because KrasG12Dmice develop tumors
more slowly than KrasG12D; Trp53fl/fl, different time points were
used to isolate cells from each model (21 and 12 weeks, respec-
tively). At these time points, the vast majority of the tumor cells in
both models are from well-established, large adenomas and ad-
enocarcinomas rather than hyperplasias (Figure S1G). Disper-
sion of Lin fluorescence+ cells in the lung parenchyma as single
cells was confirmed with immunofluorescence (Figure S1H).
Secondary tumors formed from KrasG12D or KrasG12D; Trp53fl/fl
primary tumor cells were readily detectable 16–21 weeks after
transplantation. The histology of the secondary tumors from
both models resembled the primary tumors from which they
were derived (data not shown). The vast majority of transplanted
tumor cells failed to initiate tumors, suggesting that tumor cells
from either model contain a rare fraction of TPCs. Both tumor
number and tumor volume per recipientmousewere significantly
greater in KrasG12D; Trp53fl/fl tumors (Figures 1C–1E). Approxi-
mately one of 2,012 KrasG12D; Trp53fl/fl tumor cells gave rise to
secondary tumors, while only approximately one in 40,860
KrasG12D tumor cells formed tumors (p = 0.0001; Figure S1I).
Therefore, only a small fraction of tumor cells from either model
is capable of tumor propagation, and loss of Trp53 is a significant
contributor to TPC frequency. Next, we sought to identify cell
surface markers that could enrich for the TPC population.
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Figure 1. Analysis of Tumor-Propagating Cell Frequency Using Fluorescent Reporters and Genetic Models of NSCLC
(A) Representative FACS plot of tumor cells isolated from KrasG12D; eYFPmice (left). Expression of lung markers Nkx2.1 (red bars) and Sftpc (blue bars) in tumor
cells (LinYFP+) and lineage + cells (Lin+YFP and Lin+YFP+) were assessed by RT-PCR (right; relative toHprt). Expression of each transcript in Lin+YFP cells is
set to 1 (n = 3, mean ± SEM).
(B) Representative allele-specific PCR of indicated sorted populations from tumor bearing KrasG12D; eYFP. MEFs (mouse embryonic fibroblast) derived from
KrasG12D embryos were infected with high titer cre-carrying adenovirus in vitro as positive controls. Lower band: knockin Lox-stop-Lox (LSL) KrasG12D allele
without recombination (500 bp); middle band: wild-type Kras allele (622 bp); top band: recombined LSL allele with one loxP site (650 bp).
(C) Representative ex vivo CT scan of tumors arising from intatracheal transfer of 5,000 FACS-sorted KrasG12D; tdRFP and KrasG12D; Trp53fl/fl; eYFP tumor cells
into recipient nu/nu mice. Left, pseudocolored three-dimensional reconstruction.
(D) Quantification of average tumor volume per recipient mouse (mean ± SEM) in secondary tumors fromKrasG12D; tdRFP orKrasG12D; Trp53fl/fl; eYFP tumor cells.
(E) Quantification of average tumor number per recipient mouse (mean ± SEM) in secondary tumors derived from KrasG12D; tdRFP or KrasG12D; Trp53fl/fl; eYFP
tumor cells.
See also Figure S1.
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Spheroid culture has been successfully applied to propagate
TPCs from solid tumors (Bao et al., 2006; Vermeulen et al.,
2008). We developed a spheroid culture system to propagate tu-
mor cells from both the KrasG12D and the KrasG12D; Trp53fl/fl
models. LinYFP+ single cells from freshly dissociated tumor-
bearing lungs were plated in a semisolid matrix (see Experi-
mental Procedures). As expected, spheroids were composed
only of fluorescent cells, demonstrating that they originated
from genetically labeled tumor cells (Figure 2A). In contrast,
LinYFP cells formed very few spheres (Figure S2A). Spheroids
were not detected from single cell suspensions of normal lung,indicating that nontransformed normal lung progenitor or epithe-
lial cells do not contribute to sphere formation (data not shown).
Spheres were hollow (Figure S2B) and stained positive for E-
cadherin, ZO-1 and several other epithelial markers (Figures
S2C–S2E). Sphere clonality was confirmed by plating a 1:1
mixture of YFP+ and tdRFP+ tumor cells (Figure 2B). When
FACS-sorted tumor cells were divided and used for either pul-
mosphere assay in vitro or orthotopic transplantation in vivo, a
significant correlation between frequency of sphere and tumor
formation was observed (Figure 2C), suggesting that the pulmo-
sphere assay could serve as a screening tool to identify markers
likely to confer increased tumor-propagating ability in vivo.Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc. 61
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Figure 2. Sphere Culture Enriches for Lung NSCLC Tumor-Propagating Cells
(A) Representative live cell image of a pulmosphere arising from a single cell suspension derived from a KrasG12D, Trp53fl/fl; eYFP tumor bearing mouse (6 days).
Nomarski DIC (differential interference contrast) image of sphere is shown on the left. Fluorescence image of eYFP+ sphere is shown on the right.
(B) EYFP and tdRFP mixing experiments to assess clonal origin of pulmospheres. Single cell suspensions were derived from the lungs of KrasG12D; tdRFP and
KrasG12D; eYFP tumor-bearing mice.
(C) Correlation between in vitro sphere-forming ability and in vivo tumor formation capacity by linear regression analysis.
(D) Frequency of sphere-forming cells in FACS-sorted LinFluorescence+ tumor cells in KrasG12D and KrasG12D; Trp53fl/fl genotypes.
(E) Relative quantification of cell growth in pulmospheres measured by cell titer blue (Promega). Reading at day 1 (24 hr after plating) is set to 1 (n = 3, mean ±
SEM).
(F) Percentage of proliferating spheroid cells identified by EdU staining in pulmospheres with KrasG12D and KrasG12D; Trp53fl/fl genotype. Pulmospheres were
labeled with EdU for 12 hr.
(G) Self-renewal of KrasG12D and KrasG12D; Trp53fl/fl pulmospheres was determined by passaging of single cells from enzyme-dissociated spheres (see
Experimental Procedures). Total numbers of pulmospheres after secondary and tertiary culture are normalized against the primary culture (n = 3, mean ± SEM).
Scale bars represent 50 mm in all panels.
See also Figure S2.
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Tumor-Propagating Cells in NSCLCPulmosphere-forming cells were rare among both KrasG12D;
Trp53fl/fl and KrasG12D tumor cells, although loss of Trp53
increased sphere-forming capacity approximately 3-fold (Fig-
ure 2D). As expected, KrasG12D spheres proliferated more slowly
than KrasG12D; Trp53fl/fl spheres (Figures 2E and 2F). When pri-
mary spheres were passaged, only a small percentage of cells
formed secondary spheres, suggesting that self-renewal is a
feature of only a subset of tumor cells. Notably, the total number
of pulmospheres from KrasG12D mice did not increase with pas-
sage, whereas the number of pulmospheres derived from
KrasG12D; Trp53fl/fl primary spheres increased over several pas-
sages (Figure 2G). Therefore, Trp53 appears to play an inhibitory
role in the regulation of self-renewal.
Identification of CD24+ITGB4+Notchhi Cells as TPCs in
Murine NSCLC
Next we sought to identify surface markers with the ability to
enrich for sphere-forming cells using an in vitro assay. Several
previously described cell surface markers, including CD133,
CD44, and CD166, failed to show significant enrichment of
sphere-forming capacity (Figure S3A). In contrast, CD24, which
has previously been shown to mark TPCs in other tissues (Lee
et al., 2011), marked a population of cells with increased ability
to form spheres (p = 0.0002; Figure S3A). CD24 enriched for
sphere-forming capacity independent of genotype, because
CD24+ tumor cells were highly enriched for sphere-forming
capacity in both KrasG12D and KrasG12D; Trp53fl/fl models (Fig-
ure S3B). However, CD24+ cells are a high percentage of the
total tumor cells (50%) in tumors from bothmodels, suggesting
that further enrichment of TPCs could be achieved with addi-
tional markers.
To identify additional markers that enrich for TPCs, microarray
profiling was used to identify differentially expressed genes be-
tween CD24+ and CD24 tumor cells (Table S1; Figure S3C).
Among the genes coding for surface markers with increased
expression in CD24+ cells were those for insulin growth factor re-
ceptor 1(igf1r), CD133 (Prominin1), integrin b4 (CD104, Itgb4),
and Notch3 (Notch3; Table S2). Differential expression of these
genes in CD24+ and CD24 tumor subpopulations was validated
by qRT-PCR using FACS-sorted tumor cells from both geno-
types (Figure S3D). Because Igf1r showed modest change in
expression level and CD133 had previously failed to enrich for
spheres (Figure S3A), only ITGB4 andNotch3were further tested
individually for their ability to enrich for pulmosphere-forming tu-
mor cells in the KrasG12D; Trp53fl/fl; eYFP model. Both ITGB4+
and Notch3hi tumor cells had significantly higher sphere-forming
capacity than their marker negative counterparts (Figures S3E
and S3F). Given the structural similarity and functional overlap
between Notch receptors, we extended our marker analysis to
the other three Notch paralogs. Notch1, Notch2, and Notch4
also enriched for sphere-forming capacity in the KrasG12D;
Trp53fl/fl; eYFP model (Figure S3G–S3I). In addition, tumor cells
sorted for each of the Notch receptors had higher expression
of the canonical Notch target genes Hey1 and DTX1, and lower
expression of the notch antagonists Numb and Numb-Like
(Figure S3J).
Next, a sorting strategy combining CD24, ITGB4, and Notch
1–4 (CD24+ITGB4+Notchhi) was used to determine if the combi-
nation could further enrich for pulmosphere-forming capacity(Figures 3A and 3B). Plating of CD24+ITGB4+ tumor cells led to
an 2.5 fold increase in pulmosphere-forming capacity
compared to CD24+ tumor cells (p = 0.0036) while plating of
the CD24+ITGB4+Notchhi tumor population led to an additional
2.8-fold increase (p = 0.0053) in sphere formation relative to
CD24+ITGB4+ tumor cells. Overall, CD24+ITGB4+Notchhi tumor
cells showed an 17.2-fold enrichment over the bulk LinYFP+
tumor cells (p < 0.0001; Figure 3C). A similar stepwise increase
in sphere-forming ability for CD24+ITGB4+Notchhi cells was
also observed in the KrasG12D; eYFP model (Figures S3K and
S3L). Thus, the combination of these three markers identified a
rare subpopulation of cells with an increased ability to form
spheres in vitro, independent of Trp53 loss. Enrichment for
TPCs using these markers was reproduced on three different
FACS sorters, indicating robustness to technical variability (Fig-
ures S3M and S3N).
To assess the tumor-propagating potential of CD24+ITGB4+
Notchhi tumor cells (3+ cells) relative to the remainder of tumor
cells (non-3+ cells) in vivo, ex vivo CT scanning was used to
quantify tumor number and size in recipient mice after transplan-
tation (Figure 3D). Given the consistency of the pulmosphere
assay results between KrasG12D and KrasG12D; Trp53fl/fl models
(Figure 3C; Figure S3L) and the more robust tumor grafting in
the KrasG12D; Trp53fl/flmodel (Figures 1C–1E), only the KrasG12D;
Trp53fl/fl; eYFP model was used for in vivo studies. Mice grafted
with 1,000 and 5,000 3+ tumor cells began to show signs of
morbidity earlier than those grafted with non-3+ cells at the
same dose due to a heavier tumor burden, leading to the eutha-
nasia of some animals4–6 weeks before the planned end point
(data not shown). Despite the shorter time frame in the 3+ grafts,
the average tumor number per recipient mouse was significantly
higher in this group (Figure 3E) and the average tumor size was
7.4 times larger (p = 0.02) than that of the non-3+ group (Fig-
ure 3F). Thus, sorting for 3+ cells enriches for a population of
cells with a more robust tumorigenic capacity. Furthermore,
regression analysis revealed a highly significant enrichment in
tumor-propagating cells in the 3+ population relative to the
non-3+ cells (p = 0.0007; Figure S3O). This difference in tumor
propagating capacity was not due to differential proliferation
rates because no difference in the frequency of EdU+ prolifer-
ating cells was observed between TPC (3+) and non-TPC (non-
3+) tumor cells (p = 0.8365; Figure 3G). Thus, 3+ cells are en-
riched for TPCs in vivo.
Serial Transplantation Reveals a Stable TPC Phenotype
in the CD24+ITGB4+Notchhi Population
Prior work has suggested significant plasticity in the TPC pheno-
type so that nontumorigenic cells transit into TPCs under certain
conditions (Marjanovic et al., 2013). To determine whether 3+
cells could give rise to non-3+ cells and vice versa, secondary
3+ and non-3+-derived tumors were analyzed with FACS. Sec-
ondary tumors derived from 3+ cells regenerated both 3+ and
non-3+ populations, recapitulating the heterogeneity of the orig-
inal tumors. Non-3+ derived tumors also contained some 3+
cells, although in a smaller fraction, suggesting that some plas-
ticity exists in TPC marker expression (Figure S4).
To assess the functional stability of TPCs, we conducted serial
transplantation of secondary tumors. Secondary tumors derived
from either 3+ cells (3+ donor) or non-3+ cells (non-3+ donor)Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc. 63
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Figure 3. Combined Sorting for CD24+ITGB4+Notchhi Identifies TPCs in NSCLC
(A and B) Representative FACS gating scheme (left) and the frequency of each population as a percentage of the total YFP labeled tumor cells (right) from
KrasG12D; Trp53fl/fl; eYFP mice (n = 5).
(C) Representative images for pulmosphere formation by each indicated population are shown on the left. Relative enrichment of pulmosphere forming ability
after step-wise addition of markers is shown on right. y axis is the fold enrichment of pulmospheres normalized by bulk tumor cells (LinYFP+) in KrasG12D;
Trp53fl/fl genotype. Data are the average of at least four independent experiments using tumor cells from either a single mouse or pooled donor mice. Scale bars
represent 500 mm.
(D) Representative ex vivo CT scan images for mouse lungs grafted with FACS-sorted LinYFP+CD24+ITGB4+Notchhi primary tumor cells (3+, top) and remainder
of bulk tumor cells (non-3+, bottom) with KrasG12D; Trp53fl/fl; eYFP genotype at a 1,000 cell transplantation dose.
(E) Average number of secondary tumors in primary grafting with 3+ and non-3+ tumor cells at different dose.
(F) Average size of individual secondary tumors.
(G) Frequency of EdU+ cycling cells in 3+ and non-3+ tumor subpopulations inKrasG12D; Trp53fl/fl; eYFP donor mice. Representative FACS plots from 3+ and non-
3+ cells are shown as a histogram on left and the bar chart on the right is the average of four mice. Error bars indicate mean ± SEM; p values are from two-tailed
t test.
See also Figure S3.
Cancer Cell
Tumor-Propagating Cells in NSCLC
64 Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc.
AB
C D
Figure 4. CD24+ITGB4+Notchhi Tumor Cells Display a Stable TPC Phenotype after Serial Transplantation
(A) Schematic illustration of serial transplantation experiment.
(B) Representative ex-vivo CT scan of tertiary tumors arising from 3+/+, 3+/, Non-3+/+ and Non-3+/ groups (see A for definitions).
(C and D) Quantification of average tumor volume (C) and tumor number (D) in secondary transplantation study. Error bars indicate mean ± SEM.
See also Figure S4.
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Tumor-Propagating Cells in NSCLCwere FACS sorted and transplanted into recipient mice (Fig-
ure 4A). After 16 weeks, ex vivo CT imaging revealed that 3+ cells
from 3+ donors (3+/+) were most potent in generating tertiary tu-
mors (Figure 4B) when compared with non-3+ cells from the
same donor group (3+/; Figures 4C and 4D). Statistical analysisindicated that both 3+ and non-3+ cells from a 3+ donor (3+/+
and 3+/) had increased tertiary tumor formation when
compared with tumor cells originating from a non-3+ primary
donor (non-3+/+ and non-3+/; p < 0.0001 for both tumor vol-
ume and tumor number). Taken together, these results stronglyCancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc. 65
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Figure 5. Mouse NSCLC TPCs Are Enriched after Chemotherapy, and Their Gene Signature Predicts Prognosis in Human NSCLC
(A) Schematic illustration of chemotherapy drug treatment regimen in KrasG12D; Trp53fl/fl mice. Tumor-bearing mice were treated with three doses of cisplatin
(7 mg/kg bodyweight) or control PBS on a weekly basis. Mice were sacrificed and FACS analysis was performed 72 hr after the last treatment.
(B) Average frequency of CD24+ITGB4+Notchhi population (3+ cells) within the bulk tumor (LinYFP+) in cisplatin (n = 5) or PBS (n = 3) treated mice. Error bars
indicate mean ± SEM; p value is from two-tailed t test.
(legend continued on next page)
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Tumor-Propagating Cells in NSCLCsupport the existence of a hierarchy in which 3+ cells give rise
over time to non-3+ cells with progressively diminished capacity
to propagate tumors. While non-3+ cells can give rise to 3+ cells,
these ‘‘reverted’’ 3+ cells do not have the same tumor-initiating
capacity as the original TPCs.
The CD24+ITGB4+Notchhi TPC Population Contributes
to Chemoresistance and Disease Prognosis
TPCs have been proposed to be associated with chemoresist-
ance and tumor relapse (Chen et al., 2012; Shafee et al., 2008).
However, few studies have confirmed this phenotype in vivo in
autochthonous mouse models or in human cancers. To deter-
mine whether the TPC population was enriched after treatment
of tumor-bearing mice with chemotherapy, tumor-bearing
KrasG12D; Trp53fl/fl mice were repeatedly dosed with cisplatin
or vehicle. In this tumor model, this regimen leads to 50% tu-
mor growth inhibition (Hegde et al., 2013). Cisplatin- or vehicle-
treated tumors were analyzed with FACS to assess the relative
frequency of the TPCpopulation within the bulk tumor. Repeated
doses of cisplatin led to a significant increase in TPC frequency
(p = 0.038, n = 8mice; Figures 5A and 5B). These results suggest
that the TPC population is intrinsically more chemoresistant
compared to the non-TPC population.
We hypothesized that human NSCLCs with a molecular signa-
ture more similar to TPCs may have a worse prognosis given the
relative chemoresistance of this population in mice. To test this
hypothesis, microarrays were used to identify differentially ex-
pressed genes between 3+ and non-3+ tumor cells (Table S3).
A gene expression signature consisting of 245 up- (‘‘TPC up’’)
and 205 downregulated (‘‘TPC down’’) genes in the 3+ TPC cells
was generated (Table S4; see Experimental Procedures; Fig-
ure 5C, left). Using the human orthologs of these genes, we
determined the ability of the ‘‘TPC up’’ or ‘‘TPC down’’ gene
signature to predict early stage lung adenocarcinoma patient
prognosis using a previously described approach for separation
of samples based on gene signatures (Vicent et al., 2012). Pa-
tients with increased expression of the ‘‘TPC up’’ or decreased
expression of the ‘‘TPC down’’ gene signatures had a worse
prognosis (p < 0.0001 for ‘‘TPC up’’ and p = 0.0031 for ‘‘TPC
down’’; Figure 5C, right). Together, the increase in TPCs after
chemotherapy treatment and the worse prognosis of human
samples with a ‘‘TPC like’’ signature strongly suggest the clinical
relevance of the 3+ TPC population to human NSCLC.
Notch Signaling Regulates the Self-Renewal of Non-
Small Cell Lung Cancer TPCs
Notchhi cells have increased expression of Notch target
genes (Figure S3J), suggesting that the Notch pathway may
play a role in maintaining NSCLC TPCs. To determine whether
sphere formation is Notch-dependent, we plated freshly isolated
tumor cells in the presence or absence of DAPT, a gamma-
secretase inhibitor (GSI) that blocks proteolytic processing of
Notch. DAPT-treatment significantly decreased the number of(C) Genes differentially expressed in TPC and non-TPC cells are correlated to hum
when compared with non-TPC cells. Right upper: Kaplan-Meier curve indicating
regulated in the TPC population have a worse overall survival (p = 0.0001). Righ
expression of genes downregulated in the TPC population have a worse overall
proportional hazards model.primary pulmospheres (Figure 6A). Consistent with the inhibition
of Notch signaling, DAPT treatment led to decreased expression
of the Notch target genes Hes1 and Hey1 (Figure 6B). Further-
more, inhibition of primary pulmosphere growth was rescued
by retroviral transduction of a Notch intracellular domain
(NICD), confirming that the effect of DAPT on primary pulmo-
sphere number was mediated by inhibition of canonical Notch
signaling (Figure 6C). In addition, EdU labeling demonstrated a
decrease in global proliferation of pulmosphere cells in the pres-
ence of DAPT (Figure 6D).
Only a small percentage of tumor cells within pulmospheres
have the capacity to self-renew and give rise to secondary
pulmospheres (Figure 2G). Because Notch enriches for TPCs
(Figure 3C), Notch may also be functionally required for their
self-renewal. To address this, primary KrasG12D; Trp53fl/fl pulmo-
spheres grown in the presence of DAPT or vehicle control were
dissociated and replated for secondary pulmosphere growth in
the absence of DAPT. DAPT pretreatment led to a 3.5 fold reduc-
tion in the self-renewal ability of primary spheres (p = 0.0007; Fig-
ure 6E). Conversely, primary tumor cells overexpressing the
NICD demonstrated a 4-fold increase in self-renewal upon sec-
ondary passage (p = 0.0009; Figure 6F). Taken together, these
data suggest that Notch activation is functionally important for
the self-renewal of TPCs in NSCLC.
Notch3 Plays a Critical Role in Non-Small Cell Lung
Cancer TPC Self-Renewal
GSIs inhibit activation of all Notch receptors and lead to gastro-
intestinal toxicity, limiting their clinical effectiveness. Therefore,
identification of a nonredundant role for specific Notch receptors
could provide a potential therapeutic opportunity in NSCLC. To
determine whether specific Notch receptors play nonredundant
roles in TPCs, tumor cells isolated from KrasG12D; Trp53fl/fl; eYFP
mice were transduced with two independent shRNAs against
each of the four Notch genes (Figures S5A–S5D) or a control
hairpin against GFP and plated to assess sphere growth (Fig-
ure 7A). None of the hairpins against Notch1, Notch2, or Notch4
significantly decreased primary pulmosphere number (Fig-
ure 7B). In contrast, knockdown of Notch3 led to a 5- to 6-fold
reduction in primary sphere number (p < 0.0001 for both hairpins;
Figure 7B). In addition, knockdown of Notch3 with the two inde-
pendent shRNAs led to a 60% and 70% reduction in sphere self-
renewal efficiency (p = 0.027 and p = 0.0049) upon passaging to
secondary spheres, suggesting that Notch3 plays a critical role
in self-renewal of spheres (Figure 7C).
The importance of Notch3 for TPC function was further
investigated in vivo. Freshly isolated primary tumor cells from
KrasG12D; Trp53fl/fl; eYFP mice were immediately transduced
with lentivirus carrying hairpins against either Notch3 or GFP
and grafted into nude mice by orthotopic transplantation as
described before (without any culture in vitro). Notch3
knockdown led to a 4-fold reduction in both number and size
of secondary tumors in recipient mice (p = 0.003 andan patient survival. Left: Heatmap of genes differentially expressed in TPC cells
that patients with early stage NSCLC with a higher expression of genes up-
t lower: Kaplan-Meier curve indicating that patients with NSCLC and a lower
survival (p = 0.0031). The p value for survival analysis was derived using a cox
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Figure 6. Notch Signaling Is Functionally Important for TPC Self-Renewal
(A) Effect of DAPT on primary pulmosphere growth from KrasG12D; eYFP and KrasG12D; Trp53fl/fl; eYFP models. Left panel is representative image for primary
pulmosphere growth after 7-day DAPT or DMSO treatment. The scale bar represents 100 mm. Quantification of total number of primary pulmospheres from both
genotypes is shown on the right.
(B) Expression of canonical Notch target genes Hes-1 and Hey-1 in DMSO- or DAPT-treated pulmospheres determined by qRT-PCR. The y axis is the relative
quantification of each transcript normalized against Hprt and the expression of each transcript in DMSO-treated pulmospheres is set to 1.
(C) Quantification of relative number of primary pulmospheres in DAPT- and DMSO-treated culture. Freshly isolated tumor cells from KrasG12D (n = 3) or KrasG12D;
Trp53fl/fl (n = 3) mice were infected with control or NICD-expressing retroviral vector before plating for pulmospheres.
(D) Cell proliferation in KrasG12D; Trp53fl/fl pulmospheres was assessed by a 6-hour EdU pulse labeling followed by immunofluorescence (left). Quantification of
the frequency of EdU positive KrasG12D; Trp53fl/fl cells in each pulmosphere is shown on right. The scale bar represents 50 mm.
(E) Effect of DAPT on pulmosphere self-renewal in spheres isolated from KrasG12D; Trp53fl/flmodel (n = 3mice). The y axis is the ratio of total number of secondary
spheres over number of primary spheres.
(F) Effect of constitutively active NICD on KrasG12D; Trp53fl/fl pulmosphere self-renewal (n = 3 mice). The y axis is the ratio of total number of secondary spheres
over number of primary spheres. Error bars indicate mean ± SEM; all p values are from a two-tailed t test.
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signaling is essential for tumor maintenance.
Integrity of Notch3 Signaling Is Important for Human
NSCLC
To determine whether Notch signaling plays a role in human
NSCLC, the pulmosphere assaywas applied to grow primary hu-68 Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc.man NSCLC cells isolated directly from patient samples.
Approximately 30% of primary patient samples were success-
fully cultured as pulmospheres and of these 50% could be
passaged efficiently. Successfully established human pulmo-
spheres were morphologically similar to those from mouse
tumors (Figure 8A). DAPT treatment resulted in an average of
2-fold reduction in the number of human primary spheres
CD
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Figure 7. Notch3 Regulates TPC Self-Renewal In Vitro and In Vivo
(A) Schematic illustration of knockdown studies using mouse primary tumor cells. Freshly isolated mouse primary tumor cells were infected with shRNA-carrying
lentivirus and tumor cells were then plated in vitro or orthotopically transplanted into recipient mice via intratrachael intubation.
(B) Effect of Notch1–4 shRNA on primary KrasG12D; Trp53fl/fl; eYFP pulmosphere growth (n = 3, mean ± SEM).
(C) Effect of Notch3 knockdown on KrasG12D; Trp53fl/fl; eYFP pulmosphere self-renewal (n = 3, mean ± SEM).
(D) Effect of Notch3 knockdown on the tumor-propagating capacity of TPCs in KrasG12D; Trp53fl/fl; eYFP mice by orthotopic transplantation study. The average
number of secondary tumors formed per recipient mouse is shown on the left, individual tumor sizes are plotted in the middle, and representative ex vivo CT
images are on the right. All p values are from a two-tailed t test.
See also Figure S5.
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treatment blocked self-renewal, the human pulmospheres
were dissociated and passaged for secondary growth. DAPT
pretreated spheres showed an average of 70% reduction in
self-renewal (p = 0.038; Figures 8C and 8D). Two of the samples
tested were from patients with mutations in oncogenic Kras, the
third had an EGFRmutation and the fourth waswild-type for both
Kras and EGFR (Figure S6A). Thus, the effect of DAPT is not
limited only to tumors with Kras mutation. These data support
a functional role for Notch signaling in human adenocarcinoma,
independent of genotype.As with the mouse TPCs, we sought to determine whether
Notch3 plays a specific role in human NSCLC propagation. First,
Notch3 knockdown was assessed in three established NSCLC
cell lines. NCI-H358 harbors a G12C mutation in Kras, NCI-
H1650 and NCI-H1975 are both Kras wild-type. Interestingly,
knockdown of Notch3 with three independent hairpins resulted
in significant impairment of cell growth in all three cell lines (Fig-
ure S6B). The functional role of Notch3 in human NSCLC propa-
gation was further tested with patient-derived xenograft (PDX)
models in vivo. Two independent tumors established from a sin-
gle PDX sample were infected with one of three Notch3 shRNAsCancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc. 69
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Figure 8. Notch Signaling Is Important for the Self-Renewal of Primary Tumors Cells Isolated from Human NSCLC
(A) Representative images of DAPT- and DMSO-treated primary pulmospheres derived from human NSCLC patients at day 14 of ex vivo culture. The scale bar
represents 100 mmm.
(B) Effect of DAPT on total number of human primary pulmospheres in four primary patient samples. The y axis is the total sphere number normalized to DMSO
treated culture.
(C) Representative image of secondary spheres passaged from DAPT and DMSO pretreated samples at day 14. The scale bar represents 100 mm.
(D) Effects of DAPT on human TPC self-renewal in primary patient samples.
(E) Western blot of lysates from primary PDX tumor cells infected with hairpins against either GFP (as control) or Notch3.
(F) Primary tumor cells derived from two PDX tumors were infected with hairpins against human Notch3 or GFP and injected into NSG mice subcutaneously.
Graphs show average tumor volume at indicated time points.
(legend continued on next page)
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effect on protein expression of Notch 1 or Notch 2, yet was suf-
ficient to ablate expression of Hes-1, a canonical downstream
target for Notch signaling, suggesting that Notch3 signaling is
nonredundant in these cells. Moreover, diminished Notch3
expression dramatically impaired tumor development in vivo
(Figure 8F). At the end of the study, there was a 100% tumor inci-
dence in the control group, whereas only 55% of the injections
from tumor cells infected with Notch3 hairpins formed tumors
(Figure 8G). Furthermore, an 6- to 10-fold reduction in tumor
sizewas observed in the Notch3 knockdown group as compared
with control (Figure 8H). Taken together, these data strongly sup-
port a nonredundant role for Notch3-mediated signaling in both
mouse models of NSCLC and in human NSCLC.
DISCUSSION
Using genetically engineered murine models of NSCLC, we
identified a subpopulation of tumor cells with increased tumori-
genicity based on their expression of an identified panel of
cell-surface markers; CD24, ITGB4, and Notch (3+ cells). We
demonstrate that 3+ cells have increased self-renewal proper-
ties in vitro and in vivo, which requires Notch3. Furthermore,
this requirement is conserved in human NSCLC TPCs because
GSI treatment and Notch3 knockdown severely attenuate self-
renewal and tumor propagation in NSCLC cell lines and primary
patient tumors. The 3+ cells are selected for after repeated
doses of chemotherapy, suggesting an important role for these
cells as a reservoir for chemoresistant tumor re-initiation. Impor-
tantly, we show that the gene signature that distinguishesmouse
TPCs has prognostic significance in NSCLC.
CD24, ITGB4, and Notch Are Surface Markers that
Enrich for TPCs
We developed and used an in vitro sphere assay to identify
markers that would allow us to enrich for TPCs. Starting with a
previously reported TPC marker, CD24, we observed an enrich-
ment in sphere-forming capacity over bulk tumor cells. The step-
wise addition of ITGB4 and Notch1–4 resulted in a progressive
increase in sphere formation (Figures 3A–3C). We then went on
to show that sphere forming capacity of 3+ and non-3+ cells
closely correlated with their in vivo tumor-forming capacity (Fig-
ures 3D–3F).
Intriguingly, two of the markers we identified (Notch and
ITGB4) have been suggested to be involved in lung development
and normal lung stem cells. ITGB4 has been used to isolate a
multipotent epithelial stem/progenitor population from the adult
mouse lung (Chapman et al., 2011; McQualter et al., 2010). How-
ever, it was demonstrated that ITGB4 was dispensable for their
stem cell function in vitro. Given the known role of integrins in ad-
hesions and cell-cell interactions in the normal stem cell niche, it
would be interesting to assess the role of ITGB4 in TPCs in vivo.
Notch signaling is also known to play an important role in lung
development. Notch1 and Notch ligands Jag1/2, as well as(G) Percentage of injections that formed palpable tumors at the end of xenograft
(H) Average tumor size at the end of xenograft experiment using PDX samples (lef
experiment are shown on right. Error bars indicate mean ± SEM. All p values are
See also Figure S6.Notch target genes Rbpjk, Hes1, Hes5, and Hey2, are expressed
in early murine lung epithelium and are important for the specifi-
cation of proximal lung structures (Tsao et al., 2008). Further-
more, transgenic mice overexpressing the Notch intracellular
domain in the lung epithelium show arrested differentiation of
distal lung progenitors, with impaired development of type I
and II pneumocytes (Dang et al., 2003; Guseh et al., 2009).
Thus, Notch activity blocks differentiation of the normal alveolar
epithelium. This is consistent with our finding that Notch3 is
essential for the self-renewal activity of the TPCs and suggests
that it may act by maintaining them in a less differentiated state.
Consistent with this notion, we find decreased expression of the
alveolar type II cell marker, Sftpc, in the 3+ cells (data not shown)
suggesting they may be in a less differentiated state than the
non-3+ cells.
The identification of CD24, ITGB4, and Notch as robust sur-
face markers provides an opportunity to isolate murine TPCs
prospectively. In future studies it will be interesting to determine
whether thesemarkers also play a role in identifying a population
of human tumor cells with increased self-renewal capacity. In
addition, although highly enriched for TPCs, the 3+ population
is still heterogeneous and likely only a subset of these cells are
true TPCs. It is therefore possible that other markers could
further enrich for TPCs. Efforts to identify these additional
markers are ongoing.
Critical and Nonredundant Role of Notch3 Signaling in
TPC Self-Renewal
Notch has been implicated in multiple human cancers but its role
in oncogenesis is highly context-dependent, acting as either an
oncogene or tumor suppressor depending on the disease setting
(Ranganathan et al., 2011). Previous studies have shown an as-
sociation between NSCLC disease progression and Notch
pathway activation (Dang et al., 2000;Mimae et al., 2012;Westh-
off et al., 2009) Consistent with previous studies, our findings us-
ing chemical blockade with DAPT demonstrate a global
decrease in tumor cell proliferation. Furthermore, DAPT treat-
ment decreases TPC self-renewal, while conversely, increased
Notch pathway activity results in enhanced self-renewal (Fig-
ure 6). Thus, our study underscores the role of Notch signaling
in sustaining tumor propagation in NSCLC. Such a role of Notch
signaling in NSCLC seems to be independent of Kras or Trp53
genotype, in contrast to the Trp53-dependent role of Notch in
leukemia (Beverly et al., 2005; Guo et al., 2008).
It is interesting that all four Notch receptors enrich for TPCs as
surfacemarkers but only Notch3 seems to be functionally nonre-
dundant (Figures 7B–7D and 8E–8H). This result may reflect
discordance between surface expression of Notch receptors
and activity of Notch signaling pathways. Indeed, recent studies
demonstrate low intracellular Notch signaling in acute myeloid
leukemia (AML) cells despite high expression of Notch2 at the
cell surface (Kannan et al., 2013; Lobry et al., 2013). Importantly,
Notch2 seems to suppress AML upon reactivation, highlighting
the necessity of characterizing the output of Notch signaling,experiment with PDX samples.
t). Representative images for tumors in indicated group at the end of xenograft
from a two-tailed t test. **p < 0.01.
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rooted in the availability of Notch ligands in the TPC niche. Alter-
natively, other posttranslational regulations, such as glycosyla-
tion and endocytosis inside TPC cells, may fine-tune specific
Notch activation. Further elucidation of paralog-specific activity
will lead to a better understanding of Notch signaling in NSCLC.
Relevance of Murine TPCs to Human NSCLC
Unsupervised hierarchical clustering based on gene expression
profiles of 3+ and non-3+ cells clearly demonstrates that they are
distinct tumor cell populations (Figure 5C). Importantly, the ‘‘TPC
up’’ gene expression signature identified in our study correlates
with poor prognosis in human NSCLC, while the ‘‘TPC down’’
signature correlates with good prognosis (Figure 5C), strongly
suggesting that genes involved in determining the TPC state
also drive aggressive human disease. This hypothesis is sup-
ported by our observation that the TPCs in mouse lung cancer
are enriched after repeated doses with chemotherapy, suggest-
ing that the TPC molecular machinery may contribute to chemo-
resistance (Figure 5B). These studies underscore the need to
combine studies of chemotherapy responsewith an understand-
ing of tumor cell heterogeneity if we hope to increase our ability
to modulate chemoresistance.
In addition, we show that the Notch-mediated self-renewal
observed in mouse TPCs is conserved in human NSCLC, as evi-
denced by inhibition of sphere formation and self-renewal in mul-
tiple DAPT-treated patient samples (Figures 8A–8D). In the
mouse, Notch3 knockdown, but not knockdown of Notch1, 2,
or 4, impaired the self-renewal of TPCs (Figure 7C) and dramat-
ically reduced both the incidence and size of secondary tumors
in vivo (Figure 7D). Importantly, such a nonredundant role of
Notch3 signaling is also conserved in at least some human
NSCLC because knocking down Notch3 expression in a PDX
sample also dramatically decreases tumor formation in vivo
(Figure 8).
Simultaneous inhibition of Notch1 and Notch2 has been
shown to underlie the GI toxicity associated with GSIs in clinical
trials (van Es et al., 2005) Thus, finding a nonredundant Notch
pathway in NSCLC has important therapeutic implications, as
it may help narrow the target and decrease toxicity. Taken
together, our results strongly support a critical role for Notch3
in NSCLC and specifically in TPCs and suggest that specific in-
hibition of Notch3 may be a promising target for treatment of this
devastating disease.
EXPERIMENTAL PROCEDURES
Mice
Lox-stop-Lox-KrasG12D (Jackson et al., 2001; 129 Sv/Jae), Trp53fl/fl (Jonkers
et al., 2001; FVB), Rosa26-LSL-eYFP (Srinivas et al., 2001), and Rosa26-
LSL-tdRFP (Luche et al., 2007; C57BL/6J) mice were maintained in a
viral-free environment. Mice were intranasally infected with adenoviral-Cre
(University of Iowa) between ages of 4 and 10 weeks (Jackson et al., 2001).
Tumor-bearing mice were sacrificed 12 weeks after infection for KrasG12D;
Trp53fl/fl; eYFP and 21 weeks after infection for KrasG12D; eYFP. All animal ex-
periments were approved by the Stanford University School of Medicine
Committee on Animal Care (APLAC).
FACS Sorting
Cell sorting was performed on either a BD FACSVantage SE, or a BD FACSAria
or a BD Influx, and data were analyzed with FlowJo software. Gates were es-72 Cancer Cell 24, 59–74, July 8, 2013 ª2013 Elsevier Inc.tablished by comparing FACS plot against fluorescence minus one (FMO)
sample with a cutoff of 0.5% positive cells in the FMO sample as previously
described (Herzenberg et al., 2006). Negative gates were set at least one
half-log apart from positive gates to avoid ambiguous distinctions between
weak positive and true negative cells (see Supplemental Experimental
Procedures).
Pulmosphere Culture
Live tumor cells with desired density in single cell suspension were re-
suspended in 100 ml of medium containing 50% matrigel (see Supplemental
Experimental Procedures). For self-renewal assays, a single cell suspension
from primary pulmospheres was replated with the conditions described
previously. Self-renewal was assessed as the ratio the number of secondary
pulmospheres divided by that of primary pulmospheres DAPT (EMD Chemi-
cals) containing stem cell medium was changed every other day.
Orthotopic Transplantation
Intratracheal intubation was performed using a mouse intubation pack (Hallo-
well EMC). Tumor cells were introduced into the trachea at indicated doses.
Tumor burden was assessed 16 weeks after tracheal intubation with Micro-
CT analysis of lungs (Caunt et al., 2008; see Supplemental Experimental
Procedures).
Virus Preparation and Transduction of Primary Tumor Cells
Retrovirus was made by transfecting 293FT cells with MigR1-IRES-GFP or
MigR1-ICN-IRES-GFP (gift of Dr. Warren Pear, University of Pennsylvania)
together with packaging plasmids. PLKO.1-based Notch shRNAs (Open Bio-
systems) were transfected together with packaging plasmids in 293FT cells
using FuGeneHD (Promega). A high titer virus was generated by pooling
virus-containing medium and spinning at 25,000 rpm for 2 hr to ensure
a multiplicity of infection > 20. Freshly isolated tumor cells were transduced
using a 30 min spin infection followed by incubation at 37C for 4–6 hr prior
to plating or orthotopic transplantation.
Gene Expression Analysis
Microarray analysis was performed with Agilent Whole Mouse Genome 4 3
44K arrays. Agilent Feature Extraction software 9.5 was used to analyze ac-
quired array images and obtain individual log2 ratios of background-sub-
tracted signal intensities. Significance analysis of microarrays and linear
models for microarray data were used to identify differentially expressed
genes between experimental groups. Genesets were used for survival analysis
using publicly available data (Shedden et al., 2008) collected from four different
centers as described (Vicent et al., 2012). Cox hazard ratios were calculated to
estimate the relative risk along with confidence interval and log-rank tests (see
Supplemental Experimental Procedures).
EdU Labeling
Mice were injected intraperitoneally with EdU (Invitrogen) at a dose of
100 mg/kg body weight for 16 hr before euthanasia. For EdU labeling of
spheres, 1 mM EdU was used to label spheres for a designed time before fix-
ation and embedding.
Human Primary NSCLC Samples
This study complied with federal, state, and local regulations of the Human
Research Protection Program and was approved by the Stanford Institutional
Research Board. Informed consent was obtained from all patients included in
the study.
Establishment of Patient-Derived Xenograft Tumors from Primary
Human NSCLC
Surgically removed human NSCLC tumor tissues were kept in ice-cold HBSS
(Life Technologies) until use. Tumors were cut into 1mm pieces and implanted
in the subrenal capsules in NOD-SCID-IL2Rg (NSG) mice (Jackson Labora-
tory, Bar Harbor, Maine).
Tumor Study with Patient-Derived NSCLC Xenograft Model
NSCLC tumor cells (0.5 3 106) from PDX tumors were resuspended in 100 ml
stem cell medium containing 25%matrigel and injected into the lower flanks of
Cancer Cell
Tumor-Propagating Cells in NSCLCNSG mice. Tumor size was measured with a digital caliper, and tumor volume
was calculated using volume = 0.5 3 (length) 3 (width)2.
ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession numbers for the microarray
results reported in this paper are GSE46438 and GSE46439.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.05.021.
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